Medizinische Universität Graz - Research portal
Selected Publication:
Gasser, R; Reisinger, E; Eber, B; Pokan, R; Seinost, G; Bergloff, J; Horwarth, R; Sedaj, B; Klein, W.
Cases of Lyme borreliosis resistant to conventional treatment: improved symptoms with cephalosporin plus specific beta-lactamase inhibition.
MICROB DRUG RESIST MECH E DIS. 1995; 1(4): 341-344.
Doi: 10.1089/mdr.1995.1.341
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Gasser Robert
- Co-authors Med Uni Graz
- Seinost Gerald
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We present four cases of verified late Lyme borreliosis with persistent symptoms and positive serology despite repeated courses of high-dose intravenous penicillin G and/or cephalosporins (including cefoperazone). The patients were now treated with cefoperazone 2 g plus sulbactam 1 g bid iv for 14 days. At the end of treatment, patients were symptom free and have remained so for the following 12 months. By then, IgG against Borrelia burgdorferi had decreased. It is concluded that the addition of beta-lactamase inhibitors to intravenous treatment could be beneficial in Lyme disease refractory to conventional treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Cefoperazone - administration and dosage Cefoperazone - therapeutic use
- Cephalosporins - administration and dosage Cephalosporins - therapeutic use
- Drug Resistance, Microbial -
- Drug Therapy, Combination - administration and dosage Drug Therapy, Combination - therapeutic use
- Enzyme Inhibitors - administration and dosage Enzyme Inhibitors - therapeutic use
- Female -
- Humans -
- Infusions, Intravenous -
- Lyme Disease - drug therapy Lyme Disease - microbiology Lyme Disease - physiopathology
- Male -
- Middle Aged -
- Sulbactam - administration and dosage Sulbactam - therapeutic use
- beta-Lactamases - antagonists and inhibitors